Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP حسب Zhicheng Tang (7010534)

"…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …"

Data_Sheet_1_The association between Geriatric Nutritional Risk Index and KSD disease: results from National Health and Nutrition Examination Survey 2007–2018.ZIP حسب Zhicheng Tang (7010534)

"…</p>Conclusion<p>The study underscores a significant, albeit nonlinear, association between elevated GNRI levels and decreased KSD prevalence. …"

Image_3_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.JPEG حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

Image 1_Comparison between the protective effect of the orally administered atorvastatin and safflower (Carthamus tinctorius) in hypercholesterolemic male rats.pdf حسب Haddad A. El Rabey (22248019)

"…The induced hypercholesterolemia significantly raised liver function enzymes, lipid peroxidation (14.9 ± 0.11 mg/dL), total cholesterol (273.3 ± 1.1 mg/dL), triglycerides (223.0 ± 4.1 mg/dL), low-density lipoproteins (204.7 ± 0.9 mg/dL), very low-density lipoproteins (44.6 ± 0.8 mg/dL), troponin, creatine kinase (CK), and adrenaline while decreased antioxidant enzymes, high-density lipoprotein (HDL), and vitamin D (11.1 ± 0.5 ng/mL). …"

Table 1_Comparison between the protective effect of the orally administered atorvastatin and safflower (Carthamus tinctorius) in hypercholesterolemic male rats.docx حسب Haddad A. El Rabey (22248019)

"…The induced hypercholesterolemia significantly raised liver function enzymes, lipid peroxidation (14.9 ± 0.11 mg/dL), total cholesterol (273.3 ± 1.1 mg/dL), triglycerides (223.0 ± 4.1 mg/dL), low-density lipoproteins (204.7 ± 0.9 mg/dL), very low-density lipoproteins (44.6 ± 0.8 mg/dL), troponin, creatine kinase (CK), and adrenaline while decreased antioxidant enzymes, high-density lipoprotein (HDL), and vitamin D (11.1 ± 0.5 ng/mL). …"

Image_2_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.JPEG حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

Image_1_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.JPEG حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

Table 3_Comparison between the protective effect of the orally administered atorvastatin and safflower (Carthamus tinctorius) in hypercholesterolemic male rats.docx حسب Haddad A. El Rabey (22248019)

"…The induced hypercholesterolemia significantly raised liver function enzymes, lipid peroxidation (14.9 ± 0.11 mg/dL), total cholesterol (273.3 ± 1.1 mg/dL), triglycerides (223.0 ± 4.1 mg/dL), low-density lipoproteins (204.7 ± 0.9 mg/dL), very low-density lipoproteins (44.6 ± 0.8 mg/dL), troponin, creatine kinase (CK), and adrenaline while decreased antioxidant enzymes, high-density lipoprotein (HDL), and vitamin D (11.1 ± 0.5 ng/mL). …"

Image_4_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.JPEG حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

Table_1_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.XLSX حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

<b><i>Streptococcus suis</i></b><b> </b><b>s</b><b>erotype</b><b> 5</b><b>: emerging </b><b>zoonotic </b><b>threat</b><b> with </b><b>distinct</b><b> genomic heterogeneity</b> حسب han zheng (20452463)

"…The capacity to establish infection, induce excessive pro-inflammatory cytokine production, and elevate biomarkers associated with organ damage varied significantly among HV+ strains. …"

Presentation_1_Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.pdf حسب Bin Zhang (64682)

"…In vitro experiments revealed that pretreatment with NGR1 significantly decreased AGEs-induced mitochondria injury, limited an increase in ROS, and reduced apoptosis in H9c2 cells. …"

Table 2_Comparison between the protective effect of the orally administered atorvastatin and safflower (Carthamus tinctorius) in hypercholesterolemic male rats.docx حسب Haddad A. El Rabey (22248019)

"…The induced hypercholesterolemia significantly raised liver function enzymes, lipid peroxidation (14.9 ± 0.11 mg/dL), total cholesterol (273.3 ± 1.1 mg/dL), triglycerides (223.0 ± 4.1 mg/dL), low-density lipoproteins (204.7 ± 0.9 mg/dL), very low-density lipoproteins (44.6 ± 0.8 mg/dL), troponin, creatine kinase (CK), and adrenaline while decreased antioxidant enzymes, high-density lipoprotein (HDL), and vitamin D (11.1 ± 0.5 ng/mL). …"

Data Sheet 5_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 9_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 6_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 10_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 8_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 1_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"

Data Sheet 11_Global, regional, and national burdens of congenital heart anomalies from 1990 to 2021, and projections to 2050.pdf حسب Erdengqieqieke Ye (19542808)

"…Correlation analysis revealed increasing trends of prevalence and YLDs with rising SDI, while incidence, deaths, DALYs, and YLLs demonstrated a declining trend with SDI elevation. From 2022 to 2050, the prevalence of congenital heart anomalies is projected to rise significantly, especially in the 0−4 age group, while mortality rates are expected to continue a slow downward trend, particularly in the 20−69 age group.…"